Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: Preliminary findings

Psychopharmacology

Volumn 197, Issue 4, 2008, Pages 675-681

  Simon, Naomi M ^a   Connor, Kathryn M ^b,c   Lebeau, Richard T ^a   Hoge, Elizabeth A ^a   Worthington III, John J ^a   Zhang, Wei ^b   Davidson, Jonathan R T ^b   Pollack, Mark H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DUKE UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anxiety; Augmentation; GAD; Paroxetine; Pharmacotherapy; Quetiapine; Refractory; Treatment

Indexed keywords

PAROXETINE; PLACEBO; QUETIAPINE;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; MALE; MONOTHERAPY; NAUSEA; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SLEEP FRAGMENTATION; XEROSTOMIA;

ADULT; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PERSONALITY INVENTORY; PROSPECTIVE STUDIES;

EID: 41849148995     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1087-x     Document Type: Article

References (41)

1. Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP (2003) WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 8:53-61
2. Canadian Psychiatric Association (2006) Management of anxiety disorders. Can J Psychiatry 51:1S-93S
3. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-596
4. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3:171-199
5. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
6. Bjerrum H, Allerup P, Thunedborg K, Jakobsen K, Bech P (1992) Treatment of generalized anxiety disorder: comparison of a new beta-blocking drug (CGP 361 A), low-dose neuroleptic (flupenthixol), and placebo. Pharmacopsychiatry 25:229-232
7. Brawman-Mintzer O, Knapp RG, Nietert PJ (2005) Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 66:1321-1325
8. Brawman-Mintzer O, Nietert PJ, Rynn M, Rickels K (2006) Quetiapine monotherapy in patients with GAD. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Ontario, CA
9. Denys D, van Megen H, Westenberg H (2002) Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry 63:700-703
10. Endicott J, Nee J, Harrison W, Blumenthal R (1993) Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 29:321-326
11. Gao K, Muzina D, Gajwani P, Calabrese JR (2006) Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 67:1327-1340
12. Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dube EM (2002) Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 63:577-584
13. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
14. Hamner MB, Brodrick PS, Labbate LA (2001) Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 13:141-146
15. Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP (2003) Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 23:15-20
16. Henning ER, Turk CL, Mennin DS, Fresco DM, Heimberg RG (2007) Impairment and quality of life in individuals with generalized anxiety disorder. Depress Anxiety 24:342-349
17. Katzman M, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Gendron A (2006) A flexible dose, open-label trial evaluating the efficacy and safety of quetiapine (seroquel) as adjunctive pharmacotherapy for the treatment of generalized anxiety disorder (GAD). Proceedings of the 26th Annual Meeting of the Anxiety Disorders Association of America, Miami, FL
18. Keene MS, Eaddy MT, Nelson WW, Sarnes MW (2005) Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. Am J Manag Care 11:S362-369
19. Kessler RC, Brandenburg N, Lane M, Roy-Byrne P, Stang PD, Stein DJ, Wittchen HU (2005) Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med 35:1073-1082
20. Lehmann E (1989) The dose-effect relationship of 0.5, 1.0 and 1.5 mg fluspirilene on anxious patients. Neuropsychobiology 21:197-204
21. Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L (2004) Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 65:222-229
22. Maier W, Heuser I, Philipp M, Frommberger U, Demuth W (1988) Improving depression severity assessment-II. Content, concurrent and external validity of three observer depression scales. J Psychiatr Res 22:13-19
23. Mendels J, Krajewski TF, Huffer V, Taylor RJ, Secunda S, Schless A, Sebastian JA, Semchyshyn G, Durr MJ, Melmed AS et al (1986) Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry 47:170-174
24. Menza MA, Dobkin RD, Marin H (2007) An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol 27:207-210
25. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-390
26. Nasrallah HA (2007) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13:27-35
27. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J (2006) Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 59:211-215
28. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK (2001) Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62:350-357
29. Rickels K, Rynn M, Iyengar M, Duff D (2006) Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 67:41-47
30. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D (2003) Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 160:749-756
31. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L (1997) Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 95:444-450
32. Ruscio AM, Chiu WT, Roy-Byrne P, Stang PE, Stein DJ, Wittchen HU, Kessler RC (2007) Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. J Anxiety Disord 21:662-676
33. Schweizer E (1995) Generalized anxiety disorder. Longitudinal course and pharmacologic treatment. Psychiatr Clin North Am 18:843-857
34. Sheehan DV, Burnham DB, Iyengar MK, Perera P (2005) Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 66:34-40
35. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22-33; quiz 34-57
36. Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH (2006) An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 67:381-385
37. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19
38. Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, Iyengar MK (2003) Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 64:250-258
39. Timdahl K, Carlsson A, Stening G (2007) An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum Psychopharmacol 22:315-325
40. Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JR (2007) Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 31:1464-1469
41. Wurthmann C, Klieser E, Lehmann E (1997) Side effects of low dose neuroleptics and their impact on clinical outcome in generalized anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry 21:601-609